Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
Authors
Attard, GSydes, M
Mason, M
Clarke, Noel W
Aebersold, D
de Bono, J
Dearnaley, D
Parker, C
Ritchie, A
Russell, J
Thalmann, G
Cassoly, E
Millman, R
Matheson, D
Schiavone, F
Spears, M
Parmar, M
James, N
Affiliation
The Institute of Cancer Research, London, UKIssue Date
2014-06-27
Metadata
Show full item recordAbstract
There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.Citation
Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. 2014: Eur UrolJournal
European UrologyDOI
10.1016/j.eururo.2014.05.038PubMed ID
24985962Type
ArticleLanguage
enISSN
1873-7560ae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2014.05.038
Scopus Count
Collections
Related articles
- Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
- Authors: Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F
- Issue date: 2014 Nov
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
- Authors: de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D, CARD Investigators
- Issue date: 2019 Dec 26
- Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
- Authors: Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, Brawley CD, Gilson C, Ingleby F, Gillessen S, Aebersold DM, Jones RJ, Matheson D, Millman R, Mason MD, Ritchie AWS, Russell M, Douis H, Parmar MKB, Sydes MR, Clarke NW, STAMPEDE Investigators
- Issue date: 2019 Dec
- Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
- Authors: McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, Chang P, Wagner AA, Bubley GJ, Kibel AS, Taplin ME
- Issue date: 2019 Apr 10
- Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?
- Authors: Suzman D, Eisenberger M
- Issue date: 2014 Nov